Efficacy of Vaccination Under Novel Immunomodulatory Therapies in Patients with Myasthenia Gravis : A Prospective Analysis (VaxIT-Study)

Efficacy of Vaccination Under Novel Immunomodulatory Therapies in Patients with Myasthenia Gravis : A Prospective Analysis (VaxIT-Study) - VaxIT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035834

Enrollment

Registered

2025-01-13

Start date

2025-01-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70.0

Interventions

Group 1: Evaluation of the vaccination response in patients with myasthenia gravis receiving novel immunomodulatory therapies. The vaccination response will be analysed by comparing the SARS-CoV-2 spi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Diagnosis of myasthenia gravis - Ability to give consent - Planned vaccination against SARS-COV2

Exclusion criteria

Exclusion criteria: Acute infectious disease

Design outcomes

Primary

Measure	Time frame
Change in Anti-Spike Antibody after vaccination	—

Secondary

Measure	Time frame
Immunisation status of patients undergoing immunomodulatory therapy for myasthenia gravis.	—

Countries

Germany

Contacts

Public ContactJana Zschüntzsch

Universitätsmedizin Göttingen

j.zschuentzsch@med.uni-goettingen.de+495513961803

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026